MedTrace Logo

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00691717 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-angle Glaucoma
  • Oular Hypertension

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Single administration by anterior juxtascleral depot

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

Single administration by anterior juxtascleral depot

DRUG

Anecortave Acetate Sterile Suspension, 75 mg/mL

Single administration by anterior juxtascleral depot

OTHER

Anecortave Acetate Vehicle

Single administration by anterior juxtascleral depot

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691717 on ClinicalTrials.gov